Download Free Medical Pharmacovigilance in Clinical Trials PowerPoint Presentation

Pharmacovigilance in Clinical Trials PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Pharmacovigilance in Clinical Trials".

This medical PowerPoint presentation is about pharmacovigilance in clinical trials. Pharmacovigilance is the practice of monitoring and assessing the safety of pharmaceutical products, including drugs and vaccines, throughout their life cycle. Clinical trials are an important part of pharmacovigilance because they provide an opportunity to collect safety data in a controlled environment.

During a clinical trial, the safety of the investigational product is closely monitored to identify any potential adverse reactions or safety concerns. This is done through a variety of methods, including collecting and analyzing data from study participants, conducting laboratory tests, and reviewing medical records.

In addition, clinical trial sponsors are required to report any adverse events that occur during the trial to regulatory authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This information is used to evaluate the safety and efficacy of the investigational product and to make regulatory decisions about its approval and use.

Pharmacovigilance in clinical trials is an ongoing process that continues even after the trial has ended. Post-marketing surveillance is conducted to identify any additional safety concerns that may arise once the product is available on the market. This includes monitoring for rare or unexpected adverse events that may not have been detected during the clinical trial.

Overall, pharmacovigilance is an essential part of ensuring the safety and efficacy of pharmaceutical products, and clinical trials play a crucial role in this process.

Tags : Pharmacovigilance in Clinical Trials, safety of pharmaceutical products, pharmaceuticals, pharmaceuticals PowerPoint presentations

Published on : Jun 23, 2023 | Views : 2230 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Pharmacovigilance in Clinical Trials Version 04 Feb 2021
Slide 2-

In this training course you will learn What is pharmacovigilance? What is the pharmacovigilance responsibility of the investigator in a clinical trial? What is the pharmacovigilance responsibility of the sponsor in a clinical trial?
Slide 3-

Introduction
Slide 4-

Pharmacovigilance - Introduction Pharmacovigilance – also called Drug safety Pharmakon (Greek for drug) Vigilare (Latin for to keep watch) Process and science of monitoring the safety of medicines and taking action to reduce the risks and increase the benefits of medicines EMA Guideline on good pharmacovigilance practices (GVP)
Slide 5-

Pharmacovigilance – WHY? All things are poison, and nothing is without poison; only the dose permits something not to be poisonous. Paracelsus (1493-1541)
Slide 6-

Thalidomide case In the late 50’s thalidomide was sold as OTC medication to treat several conditions, including morning sickness in pregnant women In 1961 Dr. McBride, Australian obstetrician and Dr. Lenz, German paediatrician, reported about birth defects/malformations McBride W. 1961. Thalidomide and congenital malformations. Lancet 1:358 Lenz W. 1962. Thalidomide and congenital abnormalities. Lancet 1:271–272
Slide 7-

ppt slide no 7 content not found
Slide 8-

The birth of modern Pharmacovigilance Thalidomide-caused birth defects revealed the gaps in the drug approval systems in place. The tragedy caused the approval of new regulations to ensure that medicinal products were tested in animals before their use in humans companies had systems in place to detect toxicities and act promptly Thalidomide is still marketed, but with a strict Risk Management Plan.
Slide 9-

Positive balance No medication is free of toxicities Benefit of use must be greater than risks Better knowledge = better decisions
Slide 10-

What is Pharmacovigilance*? Science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. In line with this general definition, underlying objectives of pharmacovigilance in accordance with the applicable EU legislation are: preventing harm from adverse reactions in humans arising from the use of authorised medicinal products within or outside the terms of marketing authorisation or from occupational exposure; and promoting the safe and effective use of medicinal products, in particular through providing timely information about the safety of medicinal products to patients, healthcare professionals and the public. Pharmacovigilance is therefore an activity contributing to the protection of patients’ and public health. * As per Guideline on good pharmacovigilance practices (GVP) – Annex I EMA/876333/2011 Rev. 1
Slide 11-

Pharmacovigilance includes: Adverse drug reactions Interactions with other medicinal products New effects of a medicinal product Lack of efficacy of medicinal product Misuse Dependence, abuse
Slide 12-

Steps of Pharmacovigilance Detection Assessment Understanding Prevention
Slide 13-

Definitions Adverse Event (AE) Adverse Drug Reaction (ADR) Serious Adverse Event (SAE) Serious Adverse Drug Reaction (SADR) Reference Safety Information (RSI) Suspected Unexpected Serious Adverse Reaction (SUSAR)
Slide 14-

Adverse Event (AE) Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment [Dir 2001/20/EC Art 2(m)]. An adverse event can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Slide 15-

Adverse Drug Reaction*? A response to a medicinal product which is noxious and unintended Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility * A.k.a. Adverse reaction, Adverse effect, Suspected adverse (drug) reaction, Undesirable effect
Slide 16-

AE vs ADR If the AE is considered related to the medicinal product, it is called an adverse reaction Adverse Event Reaction Relatedness
Slide 17-

“Temporal correlation does not imply causation” Adverse event: Temporal correlation Adverse reaction/effect: Causality Are the rabbit and the dog out running at the same time? (Temporal correlation) Or is the rabbit running because the dog is chasing it? (Causality)
Slide 18-

SERIOUS Adverse Event A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, The term "life-threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe. requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity is a congenital anomaly/birth defect Medically significant event Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING (CPMP/ICH/377/95)
Slide 19-

AE vs SAE If the AE is considered serious according to the defined criteria (death, hospitalisation, etc.), it is an SAE Adverse Event SAE Seriousness
Slide 20-

Serious Adverse Drug Reaction (SADR) An AE that is considered serious (as per defined criteria) AND possibly related to the medicinal product
Slide 21-

Reference Safety Information (RSI) Reference safety information, i.e. the known safety information / adverse reactions for a product The Investigator’s Brochure (IB) or Summary of Product Characteristics (SmPC) outline which adverse reactions are to be considered as expected adverse reactions, and the frequency and nature of those adverse reactions Reg (EU) No 536/2014 Annex 1.E.30 Summary of Product Characteristics (SmPC) is most commonly used as RSI in investigator initiated trials testing authorised medicinal products in accordance with the marketing authorisation
Slide 22-

SUSAR: Suspected Unexpected Serious Adverse Reaction Is the reaction known (included in the RSI)? If no, the event is considered “Unexpected” Understanding the SUSAR concept – start from the last word and move backwards The event is suspected to be related  Suspected Adverse Reaction And the event is serious  Serious Adverse Reaction And the event is unexpected  Suspected Unexpected Serious Adverse Reaction (SUSAR)
Slide 23-

Assessments Adverse Event Expectedness Adverse Event Reaction Relatedness SAE Seriousness Serious ADR SUSAR Expectedness
Slide 24-

Legal framework in the EU/Norway Good Pharmacovigilance Practices (GVP) Regulations and guidelines are collected at the EMA web site Clinical trials: Directive 2001/20/EC (valid until 536/2014 is implemented) Regulation 536/2014 (to be implemented in Dec 2021?) FOR-2009-10-30-1321: Forskrift om klinisk utprøving av legemidler til mennesker (to be updated when 536/2014 is implemented)
Slide 25-

Investigator’s Responsibilities
Slide 26-

Responsibilities Competent Authority Sponsor Investigator Patient Detection Assessment Understanding Prevention
Slide 27-

Responsibilities Sponsor Investigator Detection Assessment Understanding Prevention
Slide 28-

Investigator Detection SAE reporting, AE collection Assessment Relatedness Expectedness Understanding Investigator’s brochure Prevention Information to patients and clinical trial subjects Compliance with protocol
Slide 29-

What must be reported? Minimum elements to make a case valid (from investigator): An identifiable patient (patient number…) A product (or a study number and randomization code, for blinded studies) An event A reporter (to be able to ask for more information)
Slide 30-

What must be reported? Causality assessment: Is the event considered to be caused by the investigational medicinal product? This assessment is made by both investigator and sponsor Further desired elements: Severity Seriousness criteria Date of onset Date of last dosing of investigational medicinal product
Slide 31-

Severity assessment Grading of event e.g. mild – moderate – severe – life threatening Several AE grading scales Examples: National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI’s CTCAE; for oncology studies, see next slide) FDA/CEBR (for vaccine trials) WHO
Slide 32-

NCI’s CTCAE Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3 Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE
Slide 33-

NCI’s CTCAE
Slide 34-

Note difference between severe and serious Serious – as per defined criteria (e.g. hospitalisation, death, etc.) Severity – grading of event (e.g. mild – moderate – severe)
Slide 35-

Reporting Time Frames Investigator  Sponsor AEs Report as soon as possible (to allow for continuous safety assessment) Recorded in the CRF SAEs Report within 24 hours of becoming aware of the event Often separate report SAE report form to collect required information
Slide 36-

Documentation All AE/SAE information must be verifiable in source documents! If lab reports or other documentation is sent to sponsor as supporting documents to the SAE report, remember to remove all personal identifiers.
Slide 37-

Assessments Adverse Event Reaction Relatedness Recording in CRF
Slide 38-

Assessments – reporting Adverse Event SAE Seriousness 24h notification required Recording in CRF Adverse Event Reaction Relatedness
Slide 39-

Further AE reporting details Follow AE reporting requirements as described in the protocol Events already described in medical history are not AEs Changed severity or frequency of events in medical history need to be reported as AEs If an AE changes severity during the course (e.g. going from moderate to severe), only one AE should be reported with the maximum severity (and not one moderate AE and another severe AE) (unless protocol defines it differently)
Slide 40-

Sponsor’s Responsibilities
Slide 41-

Sponsor Detection Clinical trial notifications (AE/SAE reports) Assessment SAE assessment (SUSAR), AE assessment/signal detection, DSUR, Investigator’s Brochure, Data Monitoring Committee Understanding Ongoing risk assessment, Data Monitoring Committee, (DSUR) Prevention Information to patients and clinical trial subjects Detailed information in protocol
Slide 42-

Planning phase Clinical Trial Protocol Need for a Data Monitoring Committee? Who will act as Medical Monitor Who will take care of SUSAR reporting? What is the Reference Safety Information?
Slide 43-

Clinical Trial Protocol Must describe in detail all research procedures, summarize the scientific rationale, and the product characteristics Summary of the known and potential risks and benefits, if any, to human subjects.
Slide 44-

Clinical Trial Protocol – GCP requirements GCP section 6.8 Assessment of safety Specification of safety parameters. The methods and timing for assessing, recording, and analysing safety parameters. Procedures for eliciting reports of and for recording and reporting adverse event and intercurrent illnesses. The type and duration of the follow-up of subjects after adverse events.
Slide 45-

Clinical Trial Protocol Emergency contacts should be included, or a clear guidance given (supporting documentation, web page…) Define expedited reporting requirements Must all SAEs be reported to sponsor within 24 hours? Define other reporting requirements From when should AEs be reported? How should changes in severity be reported? How is hospitalisation defined? (Often: >24 hours)
Slide 46-

Risk Assessment According to ICH-GCP-R2 risk assessment for a clinical trial should be done as early as possible and mitigations included in the clinical trial protocol and/or other study actions Risks to be assessed: Risks to participant safety associated with the intervention(s) being tested Risks associated with design and methods Ongoing evaluation (review and update of risk assessment at regular intervals or in case of e.g. a substantial amendment)
Slide 47-

Risks related to safety reporting Possible risk adaptations to safety reporting: selective recording and reporting of adverse events adaptations to expedited reporting from the investigator to the sponsor, for certain serious adverse events. Requirements: Justification in protocol Supported by risk assessment
Slide 48-

Examples (study specific risk assessments required) Neutropenia is an expected event that requires hospitalisation in oncology trials. Protocol can define that these events are not to be reported expeditely as SAEs, but rather as regular AEs in the CRF. Risk assessment justifies that AEs should be collected only after the investigational medicinal product has been administered and not from the time of informed consent for study participation.
Slide 49-

Data Monitoring Committee (DMC) Groups of independent experts that review study data in an unblinded way Issues recommendations to the study sponsor Procedures must be documented in a charter
Slide 50-

DMC Charter The charter will be signed by all members BEFORE starting the reviews The charter contains: Stopping rules Safety issues Lack of efficacy (futility) Overwhelming evidence of efficacy Voting procedures: Open & closed sessions Meeting frequency Data provided and format
Slide 51-

DMC Recommendations are documented, and part of the Trial Master File DMC will review safety data DMC may review efficacy data at pre-determined points
Slide 52-

Need a DMC? Consider indication, study endpoint(s), study duration as well as study population and available knowledge about the investigational medicinal product. A DMC is usually not needed in low risk clinical trials.
Slide 53-

Need a Medical Monitor? YES
Slide 54-

Responsibilities of a Medical Monitor Provide input to clinical trial protocol design and risk assessments Review and analyze safety (and efficacy) data, incl. SAE assessments Project leader/national co-ordinating investigator can act as Medical Monitor
Slide 55-

Safety reports during the study SAE processing – SUSAR reporting Line listings to investigators Urgent safety measures Annual safety report (DSUR) IB updates (if IB is in use for the clinical trial)
Slide 56-

SAE processing SAEs received from investigator within 24 hours of investigator becoming aware Sponsor (Medical Monitor) must do: Causality assessment Can rely on investigator’s assessment Or do separate assessment in addition Expectedness assessment Is the event included in the Reference Safety Information (IB or SmPC)?
Slide 57-

Causality Assessment Is there a causal relationship between medication and event? YES/NO Several methods to assess relatedness Medical experience Structured scoring systems taking into consideration, i.a. Temporal association De-challenge/Re-challenge Mechanism of action Other explanation
Slide 58-

Reasonable possibility Definitely not related Unlikely related Likely related Definitely related Not related Related If the investigator can choose between several options when assessing causality, sponsor should up-front define which assessments are to be considered as “not related” and “related”  important from a regulatory reporting perspective
Slide 59-

Causality assessment Sponsor can never downgrade a causality assessment
Slide 60-

Assessments Adverse Event Expectedness Adverse Event Reaction Relatedness SAE Seriousness Serious ADR SUSAR Expectedness
Slide 61-

SUSAR: Suspected Unexpected Serious Adverse Reaction If the SAE is unexpected and related, it is a SUSAR If the investigator or the sponsor considers the SAE as “Related”, the event is considered related (i.e. the sponsor can not downgrade an event).
Slide 62-

SUSAR Reporting In case of SUSAR, expedited, unblinded reporting to: Competent Authorities* via Eudravigilance Additional requirement to inform: Ethics Committees (unless local regulations differ) Investigators * Competent authorities (CA) = Statens Legemiddelverk or similar for other countries
Slide 63-

Reporting Time Frames Sponsor  Competent Authorities (Eudravigilance database) Fatal or life threatening SUSARs Within 7 days of becoming aware Follow-up information within 8 days thereafter Other SUSARs Within 15 days But always as soon as possible
Slide 64-

Reporting Time Frames* Sponsor  Ethics Committees, if applicable Each Ethics Committee will have different requirements E.g. all SUSARs in study, or in country, or just site or none Norway: None *Slide not applicable after implementation of 536/2014. With 536/2014 the competent authorities will obtain EC comments to SUSARs
Slide 65-

Reporting Time Frames Sponsor  Investigators Line listings of blinded SUSARs In periods as warranted by the nature of the clinical development project and the volume of SUSARs generated. Should be accompanied by comments on how/if the SUSARs changes the safety profile of the test product IB update Annual review
Slide 66-

Blinded Data - Investigators Unblinding the treatment of a patient has a high impact on the validity of the data. Should only be done if knowing the treatment is essential in managing the event (e.g. antidots, interactions) Even in those cases, the investigator is encouraged to contact the sponsor before making a final decision Any unblinding must be properly documented (incl. rationale, date, name and signature of person unblinding) and sponsor must be informed
Slide 67-

Need to unblind? Competent authorities require (with some exceptions) unblinded SUSAR reports Safety team at sponsor should unblind treatment to decide reporting “path” even if investigator did NOT unblind the treatment NB! If the sponsor representative is actively involved in the clinical trial, someone else should unblind for reporting. Study team should remain blinded to treatment allocation
Slide 68-

Which SUSARs should be reported? If unblinding reveals that the SUSAR occurred in a patient receiving placebo, expedited reporting to the competent authorities is rarely required (exception: e.g. excipient reactions) Remember that reporting of SUSARs for active comparators is required
Slide 69-

Blinded studies: Reporting to CA, ethics committees (ECs) and investigators Reporting all cases to investigators maintains the blind But reporting placebo cases to CAs and ECs is misleading and inappropriate
Slide 70-

Eudravigilance (EV) Sponsors must submit SUSAR reports to competent authorities via Eudravigilance
Slide 71-

Eudravigilance European Union Drug Regulating Authorities Pharmacovigilance Safety database of the European Medicines Agency (EMA) Two modules EVPM: Post Authorisation EVCTM: Clinical Trials The cases are entered Automatically, through a EV Gateway (safety database “communicates” directly with Eudravigilance) Manually, through EVWeb (web based solution – preferred option if you have a low number of anticipated SUSARs)
Slide 72-

Eudravigilance Different types of organisations in Eudravigilance Category III: Non commercial sponsors All sponsors (institutions) have to Be registered in the EMA organisation database, SPOR Have a Responsible Person (RP) for Eudravigilance reporting The RP can delegate actual reporting of SUSARs SPOR = Substances, products, organisations and referentials
Slide 73-

Eudravigilance To use Eudravigilance, the sponsor must Have at least one trained user (unless using a 3rd party, e.g. Clinical Trial Unit) Have a valid MedDRA license Register user data in EudraVigilance Register product in the Eudravigilance product dictionary, XEVMPD (only if the product isn’t already registered) MedDRA = Medical Dictionary for Drug Regulatory Affairs XEVMPD = Extended EudraVigilance Medicinal Product Dictionary
Slide 74-

Current SUSAR reporting option (Norway, only) Current* option in Norway for non-commercial sponsors: SUSARs can be reported on paper using CIOMS form (Eudract number must be added to form) Submit form by e-mail to post@legemiddelverket.no * As per 4 February 2021
Slide 75-

Urgent Safety Measures Unexpected events that might materially influence the benefit-risk assessment of the IMP or that would lead to changes in the administration of an IMP or in overall conduct of a clinical trial must be notified to the competent authorities. Where an unexpected event is likely to seriously affect the benefit-risk balance, the sponsor and the investigator shall take appropriate urgent safety measures to protect the subjects. Any urgent safety measures taken must be reported to the competent authorities as soon as possible after measures have been taken.
Slide 76-

Development Safety Update Report (DSUR) “a comprehensive, thoughtful annual review and evaluation of pertinent safety information collected during the reporting period related to a drug under investigation” If feasible, one single DSUR with data pertinent to all dosage forms and strengths, all indications, and all patient populations under study with the investigational drug, should be written. However, the sponsor is responsible for including at least safety data from the clinical trial(s) for which the organsiation is responsible. ICH guideline E2F on development safety update report
Slide 77-

DSUR Annual report covering all participating countries The first approval date of the clinical trial in any country (called the Development International Birth Date (DIBD)) defines when the report is due. (If the first approval date of any clinical trial is not known, it is ok to use the approval date of the applicable clinical trial as “DIBD”.) The reporting period is 12 months from the DIBD. The submission deadline is 60 days after the DIBD. The DSUR should be written in English for possible use in any country.
Slide 78-

DSUR submission Under 2001/20/EC: Submitted to competent authorities and ethics committees via their regular reporting system (e-mail, database systems) Some ethics committees don’t want DSURs (example: Norwegian REK) Under 536/2014: Submitted via the EU Portal
Slide 79-

Alternative Annual Safety Report (Norway, only) Current* option in Norway for non-commercial sponsors: If the study is ongoing in Norway, only, a simpler annual report form can be submitted to the Norwegian Medicines Agency instead of the DSUR. Årsrapportskjema til Legemiddelverket Submit form by e-mail to post@legemiddelverket.no * As per 04 February 2021
Slide 80-

Investigator’s Brochure (IB) A compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. Purpose: information to facilitate study staff’s understanding of the rationale for, and their compliance with, many key features of the protocol, such as the dose, dose frequency/interval, methods of administration and safety monitoring procedures. Must be reviewed annually and revised as necessary
Slide 81-

Good luck with the safety reporting in your study!